Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP7 | P09237 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904840 | 0.89 | MAPT (0.37) | EEF2KMAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL3907542 | 0.83 | — | — | |
| SCHEMBL3908602 | 0.81 | THRB (0.41) | MAPTSLC1A3SLC1A2SLC1A1MMP13 | |
| SCHEMBL2883515 | 0.73 | POLB (0.44) | MAPTHTTSMN1; SMN2 | |
| SCHEMBL2883514 | 0.73 | POLB (0.44) | MAPTHTTSMN1; SMN2 | |
| SCHEMBL3908544 | 0.72 | PSEN1 (0.52) | EEF2KSLC1A3SLC1A2SLC1A1TRPV1 | |
| SCHEMBL6801083 | 0.72 | MMP2 (0.63) | SLC1A3SLC1A2SLC1A1MMP13MMP1 | |
| SCHEMBL6800548 | 0.72 | MMP2 (0.63) | SLC1A3SLC1A2SLC1A1MMP13MMP1 | |
| SCHEMBL3904762 | 0.70 | MMP2 (0.50) | MAPTHTTSMN1; SMN2HSD17B10SLC1A3 | |
| SCHEMBL3906115 | 0.70 | MMP2 (0.50) | MAPTHTTSMN1; SMN2HSD17B10SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221711-A1 | TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS | WYETH (US) | 2009-09-03 | — | — | US | disclosed |
| US-7550629-B2 | 4-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]benzenesulfonamide; 4-cyano-N-(3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-benzenesulfonamide; Alzheimer's Disease, amyloid angiopathy, systemic amyloidosis, mild cognitive impairment and Down's syndrome | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070249722-A1 | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors | WYETH (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221711-A1 | TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS | APP, PSEN1, BACE1 | EEF2K 4683/4885MAPT 6/4885HTT 132/4885 |
| US-20070249722-A1 | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors | APP, PSEN1, BACE1 | EEF2K 4683/4885MAPT 6/4885HTT 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.